Renewed focus
This will be my final statement as acting CEO before our new CEO Ann Gidner assumes her new role on May 9. I am pleased that I will return to focusing fully on my CFO role having overseen a productive Quarter of renewed focus that I believe will serve as a basis for strong business development.
VISION
Ziccum's vision is to increase vaccination coverage worldwide, so contributing to a more equal distribution of vaccines. We can do this by both increasing the regional production of vaccines, and simplifying how we distribute them, minimizing our dependence on expensive, energy-intensive cold and freezer chains.
confirmed cases of Covid-19 have been reporten to WHO
deaths have been reported to WHO
of people in low income countries have received at least one dose of covid-19 vaccine
cost of COVID-19 for the world economies by Jan 2022, according to IMF
ZICCUM IN SHORT
Ziccum's patented technology LaminarPace air-dries liquid vaccine into a thermostable powder vaccine. Before it is administered, the vaccine powder is mixed with liquid and can then be injected in exactly the same way as a liquid solution vaccine.
The LaminarPace technology is gentle, air-drying takes place at room temperature, resulting in powder vaccines becoming thermostable. This means that the vaccine can be transported and stored at room temperature, unlike today's vaccines that require costly, complex logistics with an unbroken freeze or cold chain.